Hannah Thomson (Moderator)
Marketing Manager, OracleBio
Date: 24 February 2021
Time: New York 11:00 | London 16:00 | Paris 17:00 | Singapore 00:00 (25 Feb) | Tokyo 01:00 (25 Feb) | Sydney 03:00 (25 Feb)
Duration: 45 minutes
Event structure: 20 minutes presentation, 15 minutes case study, 10 minutes Q&A
Registration fee: Complimentary access
Webinar on-demand: Available to view until midnight 10 March 2021 (registration is required)
OracleBio is a global leader in quantitative digital pathology services to Pharma and Biotech clients worldwide. Leveraging industry-leading image analysis software platforms, the company delivers robust data packages to support clinical trials and translational research. As image analysis experts, OracleBio specialises in cellular phenotyping of multiplex stained tissue and has built a strong reputation as the go-to company for complex image analysis.
In this webinar, Keith and Lorcan will give an overview of OracleBio’s image analysis study workflow including:
• Quality control procedures to generate data you can trust
• Integrating clinical pathologists into image analysis workflow
• Algorithm development and ensuring data integrity
• Collaboration and sharing of analysis and results via image viewing portal
• Two Case Studies giving real-world examples of how OracleBio’s services can add value to Pharma R&D
Lorcan is an image analysis expert and co-founder of OracleBio. He is highly skilled in the use of multiple image analysis software platforms (Visiopharm, Halo and Definiens) and has extensive experience in the use of histology, IHC and IF to support Pharma R&D. Prior to starting OracleBio, Lorcan spent 10 years in the pharmaceutical industry leading a group responsible for performing histology, IHC and image analysis.
Keith has worked in the Pharmaceutical industry for over 25 years, with experience in large Pharma, Biotech and the contract services sector. He has held positions of both scientific, project and people leadership, with experience across the drug Dx/Dv pipeline, from HTS to through to early clinical development support, including biomarker and translational science studies.